Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, has entered into a commercial manufacturing and supply framework agreement—CMO Agreement—with the company’s partner in China, Qilu Pharmaceutical.   Under the CMO Agreement, Qilu will be part of the contract manufacturing network for global commercial supply of Vicineum. The company’s lead program, Vicineum, is currently in the follow-up stage of a Phase 3 reg...